达仁堂高分红引关注，主业增长持续性成关键

Core Viewpoint - The company, Darentang (600329), announced a cash dividend of 2.45 yuan per share, totaling approximately 1.887 billion yuan, which represents 87.67% of its net profit attributable to shareholders for the first three quarters of 2025 [1] Company Fundamentals - Cash Flow and Financial Health: The high dividend payout reflects strong cash flow, with cash reserves of 4.032 billion yuan and a debt-to-asset ratio of only 22.1%. However, a significant portion of the dividend comes from non-recurring gains from the sale of Tianjin Shike equity, which accounted for 71.6% of net profit for the first three quarters. The core business's net profit, excluding non-recurring items, grew only by 6.7%, indicating reliance on the stability of the industrial sector for sustainable dividends [2] - Shareholder Returns and Confidence: With a payout ratio exceeding 80% and cumulative dividends exceeding 5.1 billion yuan since listing, the company strengthens long-term investor return expectations. However, if excluding one-time gains, the dividend rate based on net profit excluding non-recurring items reaches 230%, raising concerns about whether core business profitability can support such high payouts [2] Recent Stock Performance - Short-term Market Reaction: Following the dividend announcement on February 4, 2026, the stock price increased by 2.0%. However, by February 13, the closing price was 43.19 yuan, reflecting a 4.68% decline over five days, indicating cautious market sentiment regarding the sustainability of the dividend [3] - Company Valuation: The current price-to-earnings ratio (TTM) is 9.30, significantly lower than the industry average of 30. The dividend yield stands at 8.64%, well above the industry average, highlighting valuation attractiveness. However, this must be assessed in conjunction with the slowdown in core business growth, as revenue for the first three quarters of 2025 decreased by 34.59% year-on-year [3] Future Development - Dividend Sustainability Risks: The high dividend is heavily reliant on non-recurring gains, and the core business faces revenue pressure. Although the core product, Suoyao Jiexin Wan, grew by 13.34%, the growth of secondary products like Qingyan Diban remains to be validated. Without future asset disposal gains, the dividend rate may revert to the 1.5%-2% range [4] - Industry Policies and Environment: The expansion of centralized procurement in traditional Chinese medicine may suppress gross margins, currently at 74.98%. Rising costs of medicinal materials and changes in accounts receivable turnover efficiency require ongoing monitoring [4] - Conclusion: The recent high dividend enhances short-term shareholder returns and reflects financial stability, but long-term value must focus on the sustainability of core business growth, such as stabilizing net profit excluding non-recurring items and increasing core product sales. Investors should monitor quarterly growth rates excluding non-recurring items, policy developments in centralized procurement, and cost control effectiveness [4]